Guizhou Yibai Pharmaceutical Co Ltd Capital Reinvestment Ratio
Guizhou Yibai Pharmaceutical Co Ltd capital reinvestment ratio. Guizhou Yibai Pharmaceutical Co Ltd (600594) has a Capital Reinvestment Ratio of 0.21x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥33.28 Million) in capital expenditures (CN¥7.08 Million). See 600594 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Guizhou Yibai Pharmaceutical Co Ltd (2002–2025)
Capital reinvestment ratio of Guizhou Yibai Pharmaceutical Co Ltd from 2002 to 2025. This chart tracks Guizhou Yibai Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 23 annual periods. See how financially flexible is Guizhou Yibai Pharmaceutical Co Ltd to measure the company's free cash flow as a share of total liabilities.
Guizhou Yibai Pharmaceutical Co Ltd Capital Reinvestment Ratio by Year (2002–2025)
Guizhou Yibai Pharmaceutical Co Ltd capital reinvestment ratio by year from 2002 to 2025. For the full cash flow conversion analysis, see 600594 operating cash flow.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.14x | CN¥256.71 Million | CN¥34.99 Million | ▼ -87.7% |
| 2024 | 1.11x | CN¥86.87 Million | CN¥96.32 Million | ▲ +221.1% |
| 2023 | 0.35x | CN¥377.61 Million | CN¥130.38 Million | ▼ -63.1% |
| 2022 | 0.94x | CN¥345.30 Million | CN¥322.92 Million | ▲ +95.1% |
| 2021 | 0.48x | CN¥934.21 Million | CN¥447.78 Million | ▼ -55.6% |
| 2020 | 1.08x | CN¥366.66 Million | CN¥395.74 Million | ▲ +94.5% |
| 2019 | 0.55x | CN¥362.71 Million | CN¥201.28 Million | ▼ -63.0% |
| 2018 | 1.50x | CN¥214.30 Million | CN¥321.33 Million | ▲ +153.8% |
| 2017 | 0.59x | CN¥681.78 Million | CN¥402.80 Million | ▼ -32.4% |
| 2016 | 0.87x | CN¥380.62 Million | CN¥332.53 Million | ▲ +74.0% |
| 2015 | 0.50x | CN¥573.68 Million | CN¥288.02 Million | ▲ +33.3% |
| 2014 | 0.38x | CN¥541.58 Million | CN¥203.94 Million | ▼ -20.5% |
| 2013 | 0.47x | CN¥577.24 Million | CN¥273.48 Million | ▼ -34.9% |
| 2012 | 0.73x | CN¥288.01 Million | CN¥209.64 Million | ▲ +42.1% |
| 2011 | 0.51x | CN¥277.83 Million | CN¥142.34 Million | ▲ +19.3% |
| 2010 | 0.43x | CN¥115.66 Million | CN¥49.66 Million | ▼ -0.1% |
| 2009 | 0.43x | CN¥103.88 Million | CN¥44.62 Million | ▲ +29.3% |
| 2008 | 0.33x | CN¥189.26 Million | CN¥62.86 Million | ▼ -89.8% |
| 2007 | 3.26x | CN¥11.94 Million | CN¥38.97 Million | ▲ +1738.0% |
| 2006 | 0.18x | CN¥95.77 Million | CN¥17.00 Million | ▼ -96.2% |
| 2005 | 4.66x | CN¥17.38 Million | CN¥80.99 Million | ▲ +153.2% |
| 2003 | 1.84x | CN¥92.10 Million | CN¥169.47 Million | ▲ +501.0% |
| 2002 | 0.31x | CN¥73.46 Million | CN¥22.49 Million | — |